Core Insights - The Wangfujing WellTown project has exceeded 90% in leasing progress, aiming to introduce over 500 well-known domestic and international brands, with more than 60% of these brands entering Tongzhou for the first time, positioning it as the largest outlet complex in North China [1][4] Economic Development - The "Bayli" project, a major international commercial and entertainment complex, has completed construction and is in trial operation, set to officially open to the public by the end of this year, with a total investment exceeding 10 billion [2] - The region's GDP is projected to grow by over 6% annually during the 14th Five-Year Plan period, with a 10.9% growth in the first three quarters of this year, ranking second in the city [2] - Since the construction of the urban sub-center began in 2016, fixed asset investment has surpassed 960 billion, maintaining over 100 billion annually for five consecutive years [2] Industrial Growth - The industrial output value in the Tongzhou area has an average annual growth rate of 23.7% during the 14th Five-Year Plan, moving from 9th to 5th in the city, with its share increasing from 2.8% to over 6% [3] - The automotive manufacturing sector ranks 3rd in the city, while urban and pharmaceutical industries rank 3rd and 4th respectively [3] Consumer Trends - Tourism consumption in the area is expected to reach 19.7 billion in 2024, a year-on-year increase of 19.6%, and has grown 3.7 times compared to the end of the 13th Five-Year Plan [4] - The Bayli project is seen as a key driver for the "spillover effect" from Universal Studios, enhancing the region's daytime entertainment and nighttime consumption offerings [5] Project Features - The Bayli project encompasses approximately 500,000 square meters, integrating Wangfujing WellTown, NuoLan Hotel, and TingYun Town, with seamless connections to subway lines [4] - The project features a high proportion of experiential retail, with 50% of its offerings, including a 35-meter indoor waterfall and the largest naked-eye 3D screen in North China [4] Future Outlook - The opening of the Bayli project is expected to usher in a new phase of commercial prosperity and cultural vitality in the urban sub-center along the Grand Canal [6]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][48]. Core Insights - The pharmaceutical sector has shown stronger performance compared to the overall market, with a 3.29% increase in the biopharmaceutical sector, while the total A-share market declined by 0.09% [1][36]. - The report highlights a significant divergence in performance among different segments of the medical device market, with consumables growing faster than equipment and IVD products [2][19]. - The report emphasizes the long-term growth potential of the Chinese medical device market despite short-term challenges related to pricing and policy [2][20]. Summary by Sections Market Performance - The biopharmaceutical sector outperformed the overall market, with notable increases in various sub-sectors: chemical pharmaceuticals up 4.51%, bioproducts up 2.65%, medical services up 1.81%, medical devices up 1.77%, and traditional Chinese medicine up 4.08% [1][36]. Key Companies and Predictions - Major companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital are rated as "Outperform" with projected net profits for 2024 ranging from 1.4 billion to 116.7 billion CNY [4][48]. - Mindray Medical is highlighted for its strong R&D and sales capabilities, benefiting from domestic medical infrastructure and international expansion [48]. - WuXi AppTec is recognized for its comprehensive drug development services, poised to benefit from the rapid growth of the global drug development outsourcing market [48]. Investment Strategy - The report suggests focusing on undervalued stocks in the medical device and pharmacy sectors, which have already reflected risks from policies like centralized procurement [46][47]. - It recommends monitoring the clinical progress of innovative drugs overseas and emphasizes the importance of global clinical data for commercialization [47][48]. Recommended Stocks - The report lists several recommended stocks, including Mindray Medical, WuXi AppTec, Aier Eye Hospital, and others, indicating their strong market positions and growth potential [48][49].

Core Insights - Shenzhen's Plaud AI has achieved global sales of over 1 million units for its recording pen, highlighting the city's role as a hub for AI innovation [1] - The "Six Coupons" policy launched by Nanshan District aims to support various stages of enterprise development, focusing on R&D, financing, production, marketing, international expansion, and consumption [2] Group 1: Policy Initiatives - The "Six Coupons" initiative includes "Model Coupons" to address AI companies' high computing costs, offering subsidies of up to 50% of actual expenses for eligible enterprises [6] - "Interest Subsidy Coupons" provide up to 50% interest support for technology companies, with a maximum annual subsidy of 500,000 yuan per enterprise [7] - "Technology Transformation Coupons" offer up to 10 million yuan per year for industrial upgrades, reflecting the district's commitment to enhancing production efficiency [7] Group 2: Market Dynamics - 42% of Chinese enterprises are currently testing large models, with 17% integrating AI into production, indicating a growing trend in AI adoption across industries [5] - The introduction of "Flow Coupons" aims to reduce marketing costs for small and medium-sized enterprises by providing a 5% rebate on advertising expenditures [11] - "Insurance Coupons" provide up to 30% subsidies for export credit insurance, enhancing companies' confidence in international markets [12] Group 3: Economic Impact - Nanshan District's GDP reached 742.81 billion yuan in the first three quarters of the year, with a year-on-year growth of 5.8%, indicating robust economic performance [16] - The strategic emerging industries now account for over 50% of the district's GDP, showcasing the shift towards high-tech sectors like AI and robotics [16] - The "Six Coupons" initiative is designed to create a supportive ecosystem for new production forces, positioning the government as an innovation partner rather than just a regulator [16][17]

Core Viewpoint - Tianjin has auctioned a residential and educational land parcel with a total area of 34,469.9 square meters and a planned construction area of 49,288.4 square meters, with a starting price of 719 million yuan [1] Group 1: Land Auction Details - The land parcel consists of residential and educational land, with a residential plot ratio of 2.0 and an educational plot ratio of 1.0 [1] - The starting price for the land was set at 719 million yuan, translating to a starting floor price of 11,082 yuan per square meter [1] - Tianjin Jinhe Urban Renewal Industry Co., Ltd. (Tianjin Rail Transit Group) won the bid at the base price of 719 million yuan, resulting in a transaction floor price of 11,082 yuan per square meter, which adjusts to 11,821 yuan per square meter after excluding the kindergarten construction area [1]

编者按 日前，党的二十届四中全会审议通过"十五五"规划建议，明确提出"优化金融机构体系，推动各类金融 机构专注主业、完善治理、错位发展"，这为包括证券公司在内的金融机构实现高质量发展指明了方 向。近年来证券公司在持续强化经营数据等"硬指标"的同时，纷纷发力文化建设并积极承担社会责任， 不断夯实"软实力"，实现经营效益和社会效益双丰收。 为学习宣传贯彻党的二十届四中全会精神，中国证券报联合中国证券业协会推出"夯实文化软实力 积极 履责显担当"系列专题报道，旨在通过分享证券公司在加强文化建设以及服务经济、社会、环境和谐发 展方面的典型案例与先进经验，体现证券公司近年来在培育中国特色金融文化、践行行业文化理念、履 行社会责任的积极成效，共同推动证券行业高质量发展。本篇为系列报道第二篇。 2025年2月，证监会发布的《关于资本市场做好金融"五篇大文章"的实施意见》提出，积极发挥资本市 场功能，着力做好科技金融、绿色金融、普惠金融、养老金融、数字金融"五篇大文章"。申万宏源 （000166）党委书记、董事长刘健在接受中国证券报记者专访时表示，近年来，证券行业切实履行直接 融资"服务商"、资本市场"看门人"、社会财富"管 ...

2025年2月，证监会发布的《关于资本市场做好金融"五篇大文章"的实施意见》提出，积极发挥资本市 场功能，着力做好科技金融、绿色金融、普惠金融、养老金融、数字金融"五篇大文章"。申万宏源 （000166）党委书记、董事长刘健在接受中国证券报记者专访时表示，近年来，证券行业切实履行直接 融资"服务商"、资本市场"看门人"、社会财富"管理者"的职责，积极响应党中央重大决策部署，通过业 务转型与综合金融服务升级，逐步构建起服务实体经济的立体化网络，成为做好金融"五篇大文章"的重 要力量。 ● 本报记者 徐昭 林倩 刘健表示，2026年是"十五五"开局之年，中国经济和资本市场都将进入高质量发展的新阶段。申万宏源 作为国有金融企业，积极响应政策号召，将服务国家战略与自身发展相结合，继续在推动金融"五篇大 文章"落地、助力实体经济高质量发展中主动担当、积极作为，助力金融强国建设。 夯实发展基石 为高质量发展注入内生动力 一直以来，申万宏源始终夯实"治理、人才、文化"三大发展基石，将社会责任融入公司核心价值框架， 为高质量发展注入内生动力。 据刘健介绍，多年来申万宏源在甘肃省、新疆维吾尔自治区、内蒙古自治区、贵州省等地开展 ...

Summary of Key Points from the Greater China Healthcare Corporate Day Industry Overview - **Industry**: Healthcare in Greater China, including biopharma, CROs, medtech, services, pharmacies, and vaccines - **Sentiment**: Positive sentiment observed in biopharma and CRO sectors, with a focus on undervalued assets following recent market pullbacks [1][1] - **Key Companies**: Wuxi Apptec, Duality, Hansoh, 3SBio, and Tigermed highlighted as companies of interest due to their overseas businesses and partnered assets [1][1] Biopharma Insights - **R&D and Commercialization**: Most biopharma companies are on track with R&D and commercialization efforts. Innovative drug sales and milestone payments are expected to drive near-term revenues [2][2] - **Revenue Projections**: - Huadong Medicine: Rmb2 billion in 2025F and Rmb3 billion in 2026F [2][2] - Sino Biopharm: Projected organic profit growth of over 20% in 2025F and double-digit growth in 2026F [2][2] - **Pricing Pressure**: Volume-based procurement (VBP) continues to impact the generics segment, although biosimilar VBP may remain limited to provincial levels [2][2] CRO and CDMO Performance - **CDMO Orders**: Strong orders and backlog reported for CDMO companies, outperforming CROs due to robust overseas demand [3][3] - **CRO Recovery**: Mild recovery signals noted for domestic CRO demand, despite lagging booking income [3][3] Medtech Sector - **Investor Sentiment**: Generally muted, with some positive indicators in segments like in-vitro diagnosis (IVD) [4][4] - **Company Guidance**: - New Industries: Expected 10% revenue growth in 2026F [4][4] - Yuyue Medical: Anticipates 10% revenue growth for 2025F and higher growth in 2026F [4][4] - **Pharmacies and TCM**: Positive feedback received, with expectations for M&A to drive growth in 2026E [4][4] Company-Specific Updates - **Kelun Biotech**: Maintained sales target of Rmb800 million to Rmb1 billion for sac-TMT (TROP2 ADC) in 2025, with potential for significant milestone payments from 2027F [7][7] - **Abbisko**: R&D progressing well, with potential NDA submission in the US for Pimicotinib expected in Q425 [8][8] - **Hutchmed**: Maintained 2025 oncology revenue guidance of US$270-350 million, with expectations for better performance in 2026 [11][11] - **Zai Lab**: Revised down 2025 revenue guidance to over US$460 million, but noted good growth trends for Zejula [14][14] - **3SBio**: Pfizer planning multiple clinical trials for SSGJ-707, with significant near-term milestone payments expected [24][24] Vaccines and Pharmacies - **CanSino**: Highlighted a diverse product portfolio, including COVID-19 vaccines and other candidates, with healthy inventory levels [39][39] - **Gushengtang**: Targeting 10-15% organic revenue growth in 2026, with notable progress in overseas business [44][44] Risks and Challenges - **Market Risks**: Potential risks include worse-than-expected price cuts from GPO programs, intensified competition, and regulatory challenges [50][50] This summary encapsulates the key insights and projections from the Greater China Healthcare Corporate Day, highlighting the positive sentiment in the biopharma and CRO sectors, along with specific company updates and potential risks in the healthcare industry.

Core Viewpoint - The establishment of Changzhou Liyang Qifan New Industry Investment Fund Partnership (Limited Partnership) with a total investment of 1 billion RMB aims to engage in private equity investment, investment management, and asset management activities [1][2]. Group 1: Fund Information - The fund is executed by Shanghai Hengxu Chuangling Private Fund Management Co., Ltd. and has a registered capital of 1 billion RMB [1][2]. - The fund's business scope includes private equity investment, venture capital, and asset management, subject to regulatory compliance [1][2]. Group 2: Partner Information - The fund's partners include Shanghai Hengxu Chuangling Private Fund Management Co., Ltd. (24% share), Jiangsu Changzhou New Energy Industry Special Mother Fund (20% share), and Jiangsu Zhongxing Ronghe Industry Investment Co., Ltd. (10% share) among others [3]. - Other partners include Liyang New Industry Investment Fund (10% share), Shanghai Zhuiguang Julian Hard Technology Venture Capital Partnership (10% share), and Shanghai Hengyi Hao Management Consulting Partnership (9.25% share) [3].

Group 1: Industry Overview - The high-value consumables industry is undergoing significant value reconstruction due to multiple policy influences, including volume-based procurement and healthcare cost control, with a key window for value reconstruction expected in 2025 [1] - The industry is shifting from a "price game" to a "value return," with innovative products that demonstrate real clinical differentiation likely to receive reasonable premiums [1] Group 2: Innovation and Competitiveness - Domestic medical devices are transitioning from domestic substitution to entering the "global innovation" tier, with accelerated approval and commercialization of innovative devices [2] - Companies are leading trends in various medical fields, such as cardiovascular interventions and structural heart disease, with significant advancements in product offerings [2] Group 3: Global Expansion - Companies are accelerating their global presence, moving from "trade export" to "ecosystem export," with overseas revenue becoming a core growth engine [3] - Notable growth in overseas revenue has been reported, with some companies achieving over 40% of their revenue from international markets [3] Group 4: Mergers and Acquisitions - Restructuring and mergers are driving value reassessment, with leading companies optimizing their business structures through asset restructuring and cross-industry expansion [4] - Companies are focusing on continuous innovation and internationalization, with strategic acquisitions enhancing their market positions [4] Group 5: IVD Industry Dynamics - The IVD industry is facing pressures from rising costs and is expected to see increased concentration, with overseas markets becoming essential for growth [5] - Significant growth in overseas revenue has been observed, with some companies reporting over 21% growth in international sales [5] Group 6: Strategic Transformations - Companies like Shengxiang Bio are exemplifying strategic transformations through acquisitions and diversification into new markets [7] - The focus on integrating diagnostics and treatment is becoming a trend among companies aiming for comprehensive healthcare solutions [7] Group 7: Innovation and Efficiency - Continuous high R&D investment is driving product innovation, with companies launching advanced products to capture the high-end hospital market [8] - AI applications are enhancing operational efficiency within the industry, indicating a trend towards technological integration [8]

Group 1 - The core viewpoint of the article is the introduction of the "Three-Year Action Plan for Promoting the Optimization and Upgrading of Agricultural Product Processing Industry in Jiangsu Province (2025-2027)" by the Jiangsu Provincial Department of Agriculture and Rural Affairs to foster rural characteristic industries [1][2] Group 2 - The action plan includes six major initiatives: cultivating "single champion" enterprises in agricultural product processing, expanding emerging industries, enhancing processing parks, building processing clusters, promoting integrated development, and improving quality and efficiency through farmer cooperation [1] - The plan aims to create a technological innovation belt for agricultural product processing, high-quality production and processing areas, and processing clusters [1] - It emphasizes the classification and cultivation of agricultural processing enterprises, establishing a matrix of leading agricultural enterprises, and fostering champion enterprises and chain-leading enterprises [1] Group 3 - The plan promotes multi-level processing at the production site, focusing on diversified development, multi-level utilization, and value addition at various stages [2] - It supports the upgrading of processing facilities and equipment to enhance standardization, high-end, intelligent, and green levels in agricultural product processing [2] - The plan encourages the application of emerging technologies such as synthetic biology in agriculture, aiming for significant breakthroughs in areas like functional substance extraction [2] Group 4 - Jiangsu has been actively developing the agricultural product processing industry, expanding new value-added opportunities in rural industries [2] - The number of large-scale agricultural processing enterprises in Jiangsu is expected to exceed 9,000 by 2024 [2] - New industries and business formats, such as functional substance extraction and marine biology, are rapidly developing and becoming important growth engines [2]